These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 23736843)

  • 1. Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease.
    Devuyst O; Torres VE
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):459-70. PubMed ID: 23736843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?
    Janssens P; Weydert C; De Rechter S; Wissing KM; Liebau MC; Mekahli D
    Pediatr Nephrol; 2018 Mar; 33(3):395-408. PubMed ID: 28455745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Residence Time Peptide Antagonist for the Vasopressin V
    Xiong X; Wang N; Zhang Y; Zhao W; Pang N; Fu K; Zhou N; Zhou X; Guo D
    J Med Chem; 2024 Apr; 67(7):5935-5944. PubMed ID: 38509003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benzodiazepine Derivatives as Potent Vasopressin V
    Cao X; Wang P; Yuan H; Zhang H; He Y; Fu K; Fang Q; Liu H; Su L; Yin L; Xu P; Xie Y; Xiong X; Wang J; Zhu X; Guo D
    J Med Chem; 2022 Jul; 65(13):9295-9311. PubMed ID: 35579344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autosomal Dominant Polycystic Kidney Disease Therapies on the Horizon.
    Zhou JX; Torres VE
    Adv Kidney Dis Health; 2023 May; 30(3):245-260. PubMed ID: 37088527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tolvaptan, a vasopressin V
    Yamada Y; Fujiki H; Mizuguchi H; Takeshita Y; Hattori K; Ohmoto K; Aihara M; Nagano K; Isakari Y; Yamamoto M; Yamamura Y
    Nihon Yakurigaku Zasshi; 2022; 157(4):254-260. PubMed ID: 35781456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Vasopressin on the Hypothalamic-Pituitary-Adrenal Axis in ADPKD Patients during V2 Receptor Antagonism.
    Heida JE; Minović I; van Faassen M; Kema IP; Boertien WE; Bakker SJL; van Beek AP; Gansevoort RT
    Am J Nephrol; 2020; 51(11):861-870. PubMed ID: 33147589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of vasopressin antagonists.
    Torres VE
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1212-8. PubMed ID: 18434616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasopressin-2 receptor signaling and autosomal dominant polycystic kidney disease: from bench to bedside and back again.
    Rinschen MM; Schermer B; Benzing T
    J Am Soc Nephrol; 2014 Jun; 25(6):1140-7. PubMed ID: 24556353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation.
    Ho TA; Godefroid N; Gruzon D; Haymann JP; Maréchal C; Wang X; Serra A; Pirson Y; Devuyst O
    Kidney Int; 2012 Nov; 82(10):1121-9. PubMed ID: 22718190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.
    Irazabal MV; Torres VE; Hogan MC; Glockner J; King BF; Ofstie TG; Krasa HB; Ouyang J; Czerwiec FS
    Kidney Int; 2011 Aug; 80(3):295-301. PubMed ID: 21544064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on tolvaptan for autosomal dominant polycystic kidney disease.
    Poch E; Rodas L; Blasco M; Molina A; Quintana L
    Drugs Today (Barc); 2018 Sep; 54(9):519-533. PubMed ID: 30303493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of tolvaptan for autosomal dominant polycystic kidney disease.
    Baur BP; Meaney CJ
    Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
    Messchendorp AL; Spithoven EM; Casteleijn NF; Dam WA; van den Born J; Tonnis WF; Gaillard CAJM; Meijer E;
    BMC Nephrol; 2018 Dec; 19(1):368. PubMed ID: 30567514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors.
    Juul KV; Bichet DG; Nielsen S; Nørgaard JP
    Am J Physiol Renal Physiol; 2014 May; 306(9):F931-40. PubMed ID: 24598801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Inhibitors of intra-cystic secretion: novel therapies in ADPKD (Autosomal Dominant Polycystic Kidney Disease)].
    Miranda N; Miranda F; Rinaldi L; Stratigis S; Capasso G
    G Ital Nefrol; 2013; 30(1):. PubMed ID: 23832438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polycystic Kidney Disease and the Vasopressin Pathway.
    van Gastel MDA; Torres VE
    Ann Nutr Metab; 2017; 70 Suppl 1():43-50. PubMed ID: 28614813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.
    Boertien WE; Meijer E; de Jong PE; Bakker SJ; Czerwiec FS; Struck J; Oberdhan D; Shoaf SE; Krasa HB; Gansevoort RT
    Kidney Int; 2013 Dec; 84(6):1278-86. PubMed ID: 23903369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin.
    Reif GA; Yamaguchi T; Nivens E; Fujiki H; Pinto CS; Wallace DP
    Am J Physiol Renal Physiol; 2011 Nov; 301(5):F1005-13. PubMed ID: 21816754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.